Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2019 on file Net Income-$3.44M-$3.44MderivedN/M vs Q4 2019 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Operating Incomederived-$3,333,654N/M Operating Cash Flowderived-$1,487,684N/M ended Dec 31, 2020 · filed Apr 15, 2021 · 105 d after period end